Enter your email address
Submit
Write your message
International Journal of Medical Laboratory
Shahid Sadoughi University of Medical Sciences
Fri, Dec 27, 2024
[Archive]
Volume 10, Issue 4 (November 2023)
IJML 2023, 10(4): 279-305 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Montazeri F, Tajamolian M, Hosseini E S, Hoseini S M. Immunologic Factors and Genomic Considerations in Recurrent Pregnancy Loss: A Review. IJML 2023; 10 (4) :279-305
URL: http://ijml.ssu.ac.ir/article-1-493-en.html
URL: http://ijml.ssu.ac.ir/article-1-493-en.html
Biotechnology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
Abstract: (401 Views)
Recurrent pregnancy loss (RPL), which is also known as repeated miscarriage, affects around 2-3% of women who are trying to conceive. While some factors contributing to RPL have been identified, the cause of almost half of all cases remains unknown. Immunological factors have been proposed as one of the potential causes of such miscarriages. However, it is hard to track the common factors leading to RPL since the individual genomic identity of aborted fetuses is different in a family like other siblings. The immunological factors involved in the pathogenesis of miscarriage generally result from either the function of the maternal immune system attributable to her genomic background or the fetal origination established by both maternal and paternal genomic backgrounds that constitute the fetal genome.
Type of Study: Research |
Subject:
Immunology
Received: 2023/09/8 | Accepted: 2023/12/26 | Published: 2023/12/1
Received: 2023/09/8 | Accepted: 2023/12/26 | Published: 2023/12/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
